Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Land & Improvements (2016 - 2019)

Historic Land & Improvements for Myriad Genetics (MYGN) over the last 5 years, with Q3 2019 value amounting to $2.2 million.

  • Myriad Genetics' Land & Improvements fell 833.33% to $2.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $2.2 million, marking a year-over-year decrease of 833.33%. This contributed to the annual value of $2.3 million for FY2019, which is 416.67% down from last year.
  • According to the latest figures from Q3 2019, Myriad Genetics' Land & Improvements is $2.2 million, which was down 833.33% from $2.3 million recorded in Q2 2019.
  • In the past 5 years, Myriad Genetics' Land & Improvements registered a high of $2.5 million during Q4 2017, and its lowest value of $2.2 million during Q4 2016.
  • For the 5-year period, Myriad Genetics' Land & Improvements averaged around $2.3 million, with its median value being $2.3 million (2015).
  • In the last 5 years, Myriad Genetics' Land & Improvements surged by 1363.64% in 2017 and then crashed by 833.33% in 2019.
  • Myriad Genetics' Land & Improvements (Quarter) stood at $2.3 million in 2015, then decreased by 4.35% to $2.2 million in 2016, then rose by 13.64% to $2.5 million in 2017, then dropped by 4.0% to $2.4 million in 2018, then fell by 8.33% to $2.2 million in 2019.
  • Its Land & Improvements stands at $2.2 million for Q3 2019, versus $2.3 million for Q2 2019 and $2.3 million for Q1 2019.